"Calcifediol" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The major circulating metabolite of VITAMIN D3. It is produced in the LIVER and is the best indicator of the body's vitamin D stores. It is effective in the treatment of RICKETS and OSTEOMALACIA, both in azotemic and non-azotemic patients. Calcifediol also has mineralizing properties.
| Descriptor ID |
D002112
|
| MeSH Number(s) |
D04.210.500.247.222.159.478.250 D04.210.500.247.808.146.478.250 D04.210.500.812.768.196.478.250 D10.570.938.146.478.250
|
| Concept/Terms |
Calcifediol- Calcifediol
- 25-Hydroxyvitamin D 3
- 25 Hydroxyvitamin D 3
- 25-Hydroxycholecalciferol Monohydrate
- 25 Hydroxycholecalciferol Monohydrate
- Monohydrate, 25-Hydroxycholecalciferol
- 25-Hydroxyvitamin D3
- 25 Hydroxyvitamin D3
- Calcidiol
- 25-Hydroxycholecalciferol
- 25 Hydroxycholecalciferol
|
Below are MeSH descriptors whose meaning is more general than "Calcifediol".
Below are MeSH descriptors whose meaning is more specific than "Calcifediol".
This graph shows the total number of publications written about "Calcifediol" by people in this website by year, and whether "Calcifediol" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 7 | 5 | 12 |
| 2018 | 3 | 3 | 6 |
| 2019 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 1 |
| 2021 | 3 | 3 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Calcifediol" by people in Profiles.
-
Response to Letter to the Editor From Viola et al: "Calcifediol Treatment and COVID-19-related Outcomes". J Clin Endocrinol Metab. 2021 11 19; 106(12):e5281-e5282.
-
Letter to the Editor From Viola et al: "Calcifediol Treatment and COVID-19-related Outcomes". J Clin Endocrinol Metab. 2021 11 19; 106(12):e5271-e5272.
-
Calcifediol Treatment and COVID-19-Related Outcomes. J Clin Endocrinol Metab. 2021 09 27; 106(10):e4017-e4027.
-
Impact of vitamin D on the course of COVID-19 during pregnancy: A case control study. J Steroid Biochem Mol Biol. 2021 10; 213:105964.
-
Mortality in Hemodialysis Patients with COVID-19, the Effect of Paricalcitol or Calcimimetics. Nutrients. 2021 Jul 26; 13(8).
-
Vitamin D supplementation and COVID-19 risk: a population-based, cohort study. J Endocrinol Invest. 2022 Jan; 45(1):167-179.
-
Vitamin D and COVID-19 severity and related mortality: a prospective study in Italy. BMC Infect Dis. 2021 Jun 14; 21(1):566.
-
Vitamin D supplementation for the treatment of COVID-19: a living systematic review. Cochrane Database Syst Rev. 2021 05 24; 5:CD015043.
-
Calcifediol Treatment and Hospital Mortality Due to COVID-19: A Cohort Study. Nutrients. 2021 May 21; 13(6).
-
Lack of association between vitamin D insufficiency and clinical outcomes of patients with COVID-19 infection. BMC Infect Dis. 2021 May 18; 21(1):450.